tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Stoke Therapeutics price target lowered to $28 from $29 at BTIG

BTIG analyst Thomas Shrader lowered the firm’s price target on Stoke Therapeutics (STOK) to $28 from $29 and keeps a Buy rating on the shares. The company’s 36-month data for Zorevunersen seems to bury any remaining question, demonstrating seizure reductions deepening in the third year of treatment for patients that started at sub-optimal loading doses and starting and staying impressive for patients that started on the 45 mg loading doses, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1